clomiphene citrate

Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

clomiphene citrate (clomifene (UK))

Clomid, Serophene

Pharmacologic class: Chlorotrianisene derivative

Therapeutic class: Fertility drug, ovulation stimulant

Pregnancy risk category X


Binds with estrogen receptors in cytoplasm, increasing secretion of folliclestimulating hormone, luteinizing hormone, and gonadotropin in hypothalamus and pituitary gland. These actions induce ovulation.


Tablets: 50 mg

Indications and dosages

Ovarian failure

Adults: 50 mg/day P.O. for 5 days starting any time in patients with no recent uterine bleeding; or 50 mg/day P.O. starting on fifth day of menstrual cycle. If ovulation doesn't occur, increase to 100 mg/day P.O. for 5 days. Start next course of therapy as early as 30 days after previous course. If patient doesn't respond after three courses, no further doses are recommended.

Off-label uses

• Male sterility (controversial)


• Hepatic disease

• Organic intracranial lesions

• Uncontrolled thyroid or adrenal dysfunction

• Ovarian cyst

• Abnormal uterine bleeding or bleeding of undetermined origin

• Pregnancy




• Obtain pregnancy test before therapy begins.

• Be aware that patient should undergo pelvic and eye examinations before starting therapy.

Adverse reactions

CNS: nervousness, insomnia, dizziness, light-headedness

CV: vasomotor flushing

EENT: visual disturbances

GI: nausea; vomiting; abdominal discomfort, distention, and bloating

GU: breast tenderness, ovarian enlargement, multiple pregnancies, birth defects in resulting pregnancies, ovarian hyperstimulation syndrome, uterine bleeding


None significant

Patient monitoring

• Monitor patient for bleeding and other adverse reactions.

Patient teaching

Instruct patient to immediately report signs and symptoms of ovarian hyperstimulation syndrome, including nausea, vomiting, diarrhea, abdominal or pelvic pain, and swelling in hands or legs.

• Tell patient to report bleeding.

• Advise patient not to take drug if she is or may become pregnant.

• Inform patient that drug increases risk of multiple births, which heightens maternal risk.

• As appropriate, review all other significant and life-threatening adverse reactions.

clomiPHENE citrate

a nonsteroidal drug that acts to stimulate ovulation by interacting with estrogen receptors in the hypothalamus in a manner that leads to the release of pituitary gonadotropins.
indications It is prescribed primarily for the treatment of anovulation and oligoovulation in women desiring pregnancy.
contraindications Abnormal vaginal bleeding, liver dysfunction, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the more serious adverse reactions are enlargement of the ovaries, hot flashes, blurred vision, gastric upset, rashes, and abdominal pain.

clomiphene citrate

Clomid® Obstetrics An ovulation-inducing agent–'fertility drug', which acts by releasing gonadotropins from the pituitary; CC ↑ multiple gestations, and ↑ the risk–RR = 2.3 of borderline or invasive ovarian tumors

clomiphene citrate

a fertility drug that stimulates secretion of pituitary gonadotropin by blocking estrogen receptors in the pituitary and hypothalamus; used to stimulate ovulation.
References in periodicals archive ?
Clomiphene citrate versus metformin as first line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Predictors of patient responses to ovulation induction with clomiphene citrate in patients with polycystic ovary syndrome experiencing infertility.
This approach is easy to use in clinical practice and constitutes an appealing alternative to clomiphene citrate, considering that metformin has well-established long-term safety, good tolerability, and that it acts on insulin resistance," Dr.
Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate.
Group A received100-200mg clomiphene citrate daily while group 2 received letrazole (2.
Approximately 20-25% of women show no response to clomiphene Citrate and are considered to be resistant.
The first is on the optimal use of the most widely prescribed medication for fertility, clomiphene citrate.
A case of CRVO secondary to clomiphene citrate has been reported.
Women who have taken clomiphene citrate for fertility problems may be at a higher risk for uterine cancer.
The treatment group was composed of 24 women who were given a continuous oral monophasic contraceptive for 42-50 days and, following withdrawal bleeding, were given 100 mg of clomiphene citrate on days 5-9 of their cycles.